These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

583 related items for PubMed ID: 14660986

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. ST-segment recovery and prognosis in patients with ST-elevation myocardial infarction reperfused by prehospital combination fibrinolysis, prehospital initiated facilitated percutaneous coronary intervention, or primary percutaneous coronary intervention.
    Thiele H, Scholz M, Engelmann L, Storch WH, Hartmann A, Dimmel G, Pfeiffer D, Schuler G, Leipzig Prehospital Fibrinolysis Group.
    Am J Cardiol; 2006 Nov 01; 98(9):1132-9. PubMed ID: 17056313
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial.
    ADVANCE MI Investigators.
    Am Heart J; 2005 Jul 01; 150(1):116-22. PubMed ID: 16084157
    [Abstract] [Full Text] [Related]

  • 7. New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines.
    Spinler SA, Hilleman DE, Cheng JW, Howard PA, Mauro VF, Lopez LM, Munger MA, Gardner SF, Nappi JM.
    Ann Pharmacother; 2001 May 01; 35(5):589-617. PubMed ID: 11346067
    [Abstract] [Full Text] [Related]

  • 8. What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
    Brodie BR.
    Catheter Cardiovasc Interv; 2008 May 01; 71(6):816-21. PubMed ID: 18412079
    [Abstract] [Full Text] [Related]

  • 9. Relationship between therapeutic time intervals and intermediate term left ventricular systolic function in patients treated with facilitated percutaneous coronary intervention for acute myocardial infarction.
    Meyborg P, Abdel-Wahab M, Herrmann G, Geist V, Khattab AA, Krüger D, Lins M, Toelg R, Simon R, Richardt G.
    Clin Res Cardiol; 2007 Feb 01; 96(2):94-102. PubMed ID: 17160565
    [Abstract] [Full Text] [Related]

  • 10. Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI).
    Di Mario C, Bolognese L, Maillard L, Dudek D, Gambarati G, Manari A, Guiducci V, Patrizi G, Rusconi LC, Piovaccari G, Hibon AR, Belpomme V, Indolfi C, Olivari Z, Steffenino G, Zmudka K, Airoldi F, Panzarasa R, Flather M, Steg PG.
    Am Heart J; 2004 Sep 01; 148(3):378-85. PubMed ID: 15389222
    [Abstract] [Full Text] [Related]

  • 11. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study.
    Armstrong PW, WEST Steering Committee.
    Eur Heart J; 2006 Jul 01; 27(13):1530-8. PubMed ID: 16757491
    [Abstract] [Full Text] [Related]

  • 12. Management of ST-elevation myocardial infarction: an update on pharmacoinvasive recanalization.
    Kashani A, Giugliano RP.
    Am J Cardiovasc Drugs; 2008 Jul 01; 8(3):187-97. PubMed ID: 18533739
    [Abstract] [Full Text] [Related]

  • 13. The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends.
    Campbell KR, Ohman EM, Cantor W, Lincoff AM.
    Am J Cardiol; 2000 Apr 27; 85(8A):32C-8C. PubMed ID: 10793178
    [Abstract] [Full Text] [Related]

  • 14. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis.
    Montalescot G, Borentain M, Payot L, Collet JP, Thomas D.
    JAMA; 2004 Jul 21; 292(3):362-6. PubMed ID: 15265852
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
    Ellis SG, Armstrong P, Betriu A, Brodie B, Herrmann H, Montalescot G, Neumann FJ, Smith JJ, Topol E, Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events Investigators.
    Am Heart J; 2004 Apr 21; 147(4):E16. PubMed ID: 15077099
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. STEMI interventions--a review of relevant clinical trials.
    Mehta S, Patlola RR, Cohen S, Falcao E, Flores AI, Soles EO.
    Indian Heart J; 2009 Apr 21; 61(2):191-206. PubMed ID: 20039507
    [Abstract] [Full Text] [Related]

  • 19. Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial.
    de Lemos JA, Gibson CM, Antman EM, Murphy SA, Morrow DA, Schuhwerk KC, Schweiger M, Coussement P, Van de Werf F, Braunwald E, TIMI 14 Investigators.
    Am Heart J; 2001 Apr 21; 141(4):592-8. PubMed ID: 11275925
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.